{"entity":{"id":"paper-mina-lebanon-drug-registration-collapse-plosone-2025","kind":"paper","name":"The collapse of new medicine registration in Lebanon after the 2019 crisis","aka":[],"tldr":"Before Lebanon's crisis, 43.6% of new FDA-approved medicines were registered in Lebanon; for those approved from 2020 to 2024 the figure was 0%, which interviewees linked to an informal policy to hold back costly new medicines.","summary":"Published as \"Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis\". The authors compared innovative medicines approved by the FDA or the EMA from 2014 to 2024 with their registration in Lebanon, before (2014 to 2019) and after (2020 to 2024) the crisis, and interviewed policymakers, industry leaders and healthcare providers about why registration slowed.","asOf":"2026-11-11","links":[{"label":"PLOS ONE 2025","url":"https://doi.org/10.1371/journal.pone.0330585"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41452850/"}],"tags":[],"related":["global-oncology-access"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lebanon-ministry-of-public-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"PLOS ONE","year":2025,"doi":"10.1371/journal.pone.0330585","pmid":"41452850","authors":"Mina W, Nahas H, Lteif MR, et al.","paperType":"methods","findings":["The share of FDA-approved innovative medicines registered in Lebanon fell from 43.6% to 0%, and of EMA-approved ones from 59.4% to 0%.","Before the crisis average registration time was under two years; after it, delays are estimated to exceed four years.","Interviewees described delayed registration as a way to contain costs and reimbursement pressure on the Ministry of Public Health, with the cost of pushing patients to parallel imports."],"whatItMeans":"A new cancer medicine approved abroad since 2020 is unlikely to be registered in Lebanon, so patients and doctors depend on older medicines, generics, biosimilars or imports outside the registered market.","caveats":["Counts registration only, not whether medicines reached patients by other routes.","The interview findings describe stakeholders' views of an informal policy, not a written one."]},"route":"/key-papers/paper-mina-lebanon-drug-registration-collapse-plosone-2025/","neighbours":{"technology":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"}],"institution":[{"id":"lebanon-ministry-of-public-health","kind":"institution","name":"Ministry of Public Health, Lebanon","route":"/institutions/lebanon-ministry-of-public-health/"}]}}